- Home
- PRK vs CGON Comparison
PRK vs CGON Comparison
Compare PRK & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRK
- CGON
- Stock Information
- Founded
- PRK 1908
- CGON 2010
- Country
- PRK United States
- CGON United States
- Employees
- PRK N/A
- CGON 61
- Industry
- PRK Major Banks
- CGON
- Sector
- PRK Finance
- CGON
- Exchange
- PRK Nasdaq
- CGON NYSE
- Market Cap
- PRK 3.1B
- CGON 2.2B
- IPO Year
- PRK N/A
- CGON 2024
- Fundamental
- Price
- PRK $191.94
- CGON $32.84
- Analyst Decision
- PRK Hold
- CGON Strong Buy
- Analyst Count
- PRK 2
- CGON 8
- Target Price
- PRK $130.00
- CGON $63.88
- AVG Volume (30 Days)
- PRK 68.6K
- CGON 396.6K
- Earning Date
- PRK 10-28-2024
- CGON 11-12-2024
- Dividend Yield
- PRK 1.65%
- CGON N/A
- EPS Growth
- PRK 1.92
- CGON N/A
- EPS
- PRK 8.46
- CGON N/A
- Revenue
- PRK $484,274,000.00
- CGON $684,000.00
- Revenue This Year
- PRK N/A
- CGON $411.76
- Revenue Next Year
- PRK $1.47
- CGON $405.27
- P/E Ratio
- PRK $22.76
- CGON N/A
- Revenue Growth
- PRK 2.58
- CGON 258.12
- 52 Week Low
- PRK $109.65
- CGON $25.77
- 52 Week High
- PRK $207.51
- CGON $50.23
- Technical
- Relative Strength Index (RSI)
- PRK 58.67
- CGON 41.08
- Support Level
- PRK $188.67
- CGON $35.12
- Resistance Level
- PRK $200.00
- CGON $40.47
- Average True Range (ATR)
- PRK 7.04
- CGON 1.69
- MACD
- PRK 1.14
- CGON -0.28
- Stochastic Oscillator
- PRK 60.45
- CGON 4.57
About PRK Park National Corporation
Park National Corp is a diversified financial services company based in Newark, Ohio, consisting of 11 community banking divisions with more than 100 offices in Ohio and Kentucky. Park National provides banking and other financial services to consumers and businesses.
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.